Polyomaviruses of nonhuman primates: Implications for research

Comparative Medicine

Volumn 58, Issue 1, 2008, Pages 51-56

  Simon, Meredith A ^a  

^a CHARLES RIVER LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NATALIZUMAB; POLIOMYELITIS VACCINE; VIRUS ANTIBODY; VIRUS DNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BABOON; CHIMPANZEE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG MECHANISM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL PNEUMONIA; KIDNEY INJURY; LEUKOENCEPHALOPATHY; LUNG LESION; MACACA; MENINGOENCEPHALITIS; MONKEY; NEPHRITIS; NONHUMAN; PATHOGENESIS; POLYOMA VIRUS; REVIEW; SEROPREVALENCE; SIMIAN VIRUS 40; VIRUS IDENTIFICATION; VIRUS INFECTION; VIRUS TRANSMISSION;

ANIMALS; ASTROCYTES; CALLITHRIX; CERCOPITHECUS AETHIOPS; DNA VIRUSES; HUMANS; MACACA; PAN TROGLODYTES; PAPIO; PHYLOGENY; POLYMERASE CHAIN REACTION; POLYOMAVIRUS; POLYOMAVIRUS INFECTIONS; PRIMATE DISEASES; PRIMATES; TUMOR VIRUS INFECTIONS;

EID: 40949096077     PISSN: 15320820     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. Aksamit AJ Jr. 1995. Progressive multifocal leukoencephalopathy: a review of the pathology and pathogenesis. Microsc Res Tech 32:302-311.
2. Allander T, Andreasson K, Gupta S, Bjerkner A, Bogdanovic G, Persson MA, Dalianis T, Ramqvist T, Andersson B. 2007. Identification of a third human polyomavirus. J Virol 81:4130-4136.
3. Ashkenazi A, Melnick JL. 1962. Induced latent infection of monkeys with vacuolating SV40 papovavirus. Virus in kidneys and urine. Proc Soc Exp Biol Med 111:367-372.
4. Axthelm MK, Koralnik IJ, Dang X, Wuthrich C, Rohne D, Stillman IE, Letvin NL. 2004. Meningoencephalitis and demyelination are pathologic manifestations of primary polyomavirus infection in immunosuppressed rhesus monkeys. J Neuropathol Exp Neurol 63:750-758.
5. Berger JR, Houff S. 2006. Progressive multifocal leukoencephalopathy: lessons from AIDS and natalizumab. Neurol Res 28:299-305.
6. Bergsagel DJ, Finegold MJ, Butel JS, Kupsky WJ, Garcea RL. 1992. DNA sequences similar to those of simian virus 40 in ependymomas and choroid plexus tumors of childhood. N Engl J Med 326:988-993.
7. Bialasiewicz S, Whiley DM, Lambert SB, Gould A, Nissen MD, Sloots TP. 2007. Development and evaluation of real-time PCR assays for the detection of the newly identified KI and WU polyomaviruses. J Clin Virol 40:9-14.
8. Bocchetta M, Di R, Powers I, Fresco A, Tosolini R, Testa A Jr, Pass HI, Rizzo P, Carbone M. 2000. Human mesothelial cells are unusually susceptible to simian virus 40-mediated transformation and asbestos cocarcinogenicity. Proc Natl Acad Sci USA 97:10214-10219.
9. Bofill-Mas S, Albinana-Gimenez N, Pipkin PA, Minor P, Gironer R. 2004. Isolation of SV40 from the environment of a colony of cynomolgus monkeys naturally infected with the virus. Virology 330:1-7.
10. Butel JS, Lednicky JA. 1999. Cell and molecular biology of simian virus 40: implications for human infections and disease. J Natl Cancer Inst 91:119-134.
11. Cantalupo P, Doering A, Sullivan CS, Pal A, Peden KW, Lewis AM, Pipas JM. 2005. Complete nucleotide sequence of polyomavirus SA12. J Virol 79:13094-13104.
12. Carbone M, Pass HI, Rizzo P, Marinetti M, di Muzio M, Mew DJY, Levine AS, Procopio A. 1994. Simian virus 40-like DNA sequences in human pleural mesothelioma. Oncogene 9:1781-1790.
13. Carbone M, Rdzanek MA, Rudzinski JJ, De Marco MA, Bocchetta M, Ramos NM, Mossman B, Pass HI. 2005. SV40 detection in human tumor specimens. Cancer Res 65:10120-10121.
14. Carbone M, Rizzo P, Pass HI. 1997. Simian virus 40, polio vaccines, and human tumors: a review of recent developments. Oncogene 15:1877-1888.
15. Carbone M, Stach R, Di Resta I, Pass HI, Rizzo P. 1998. Simian virus 40 oncogenesis in hamsters. Dev Biol Stand 94:273-279.
16. Carter JJ, Madeleine MM, Wipf GC, Garcea RL, Pipkin PA, Minor PD, Galloway DA. 2003. Lack of serologic evidence for prevalent simian virus 40 infection in humans. J Natl Cancer Inst 95:1522-1530.
17. Carville A. 2007. Personal communication.
18. Cole CN, Conzen SD. 2001. Polyomaviridae: the viruses and their replication. In: Knipe DM, Howley PM, editors. Fields virology. Philadelphia: Lippincott Williams & Wilkens. p. 2141-2174.
19. Cristaudo A, Foddis R, Vivaldi A, Buselli R, Gattini V, Guglielmi G, Cosentino F, Ottenga F, Ciancia E, Libener R, Filiberti R, Neri M, Betta P, Tognon M, Mutti L, Puntoni R. 2005. SV40 enhances the risk of malignant mesothelioma among people exposed to asbestos: a molecular epidemiologic case-control study. Cancer Res 65:3049-3052.
20. Cutrone R, Lednicky J, Dunn G, Rizzo P, Bocchetta M, Chumakoy K, Minor P, Carbone M. 2005. Some Oral Poliovirus Vaccines Were Contaminated with Infectious SV40 after 1961. Cancer Res 65:10273-10279.
21. Eizuru Y, Sakihama K, Minamishima Y, Hayashi T, Sumiyoshi A. 1993. Re-evaluation of a case of progressive multifocal leukoencephalopathy previously diagnosed as simian virus 40 (SV40) etiology. [published erratum appears in Acta Pathol Jpn 43:535] Acta Pathol Jpn 43:327-332.
22. Engels EA, Switzer WM, Heneine W, Viscidi RP. 2004. Serologic evidence for exposure to simian virus 40 in North American zoo workers. J Infect Dis 190:2065-2069.
23. Gardner SD, Field AM, Coleman DV, Hulme B. 1971. New human papovavirus (BK) isolated from urine after renal transplantation. Lancet 1:1253-1257.
24. Gardner SD, Knowles WA, Hand JF, Porter AA. 1989. Characterization of a new polyomavirus (Polyomavirus papionis 2) isolated from baboon kidney cell cultures. Arch Virol 105:223-233.
25. Gaynor AM, Nissen MD, Whiley DM, Mackay IM, Lambert SB, Wu G, Brennan DC, Storch GA, Sloots TP, Wang D. 2007. Identification of a novel polyomavirus from patients with acute respiratory tract infections. PLoS Pathog 3:e64.
26. Gazdar AF, Butel JS, Carbone M. 2002. SV40 and human tumours: myth, association, or causality? Nat Rev Cancer 2:957-964.
27. Geissler E. 1990. SV40 and human brain tumors. Prog Med Virol 37:211-222.
28. Gross L. 1953. A filterable agent, recovered from Ak leukemic extracts, causing salivary gland carcinomas in C3H mice. Proc Soc Exp Biol Med 83:414-421.
29. Horvath CJ, Simon MA, Bergsagel DJ, Pauley DR, King NW, Garcea RL, Ringler DJ. 1992. Simian virus 40-induced disease in rhesus monkeys with simian acquired immunodeficiency syndrome. Am J Pathol 140:1431-1440.
30. Hurley JP, Ilyinskii PO, Horvath CJ, Simon MA. 1997. A malignant astrocytoma containing simian virus 40 DNA in a macaque infected with simian immunodeficiency virus. J Med Primatol 26:172-180.
31. Ilyinskii PO, Daniel MD, Horvath CJ, Desrosiers RC. 1992. Genetic analysis of simian virus 40 from brains and kidneys of macaque monkeys. J Virol 66:6353-6360.
32. Jasani B, Cristaudo A, Emri SA, Gazdar AF, Gibbs A, Krynska B, Miller C, Mutti L, Radu C, Tognon M, Procopio A. 2001. Association of SV40 with human tumours. Semin Cancer Biol 11:49-61.
33. Johne R, Enderlein D, Nieper H, Muller H. 2005. Novel polyomavirus detected in the feces of a chimpanzee by nested broad-spectrum PCR. J Virol 79:3883-3887.
34. Jones-Engel L, Engel GA, Heidrich J, Chalise M, Poudel N, Viscidi R, Barry PA, Allan JS, Grant R, Kyes R. 2006. Temple monkeys and health implications of commensalism, Kathmandu, Nepal. Emerg Infect Dis 12:900-906.
35. Kleinschmidt-DeMasters BK, Tyler KL. 2005. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon β1a for multiple sclerosis. N Engl J Med 353:369-374.
36. Krainer M, Schenk T, Zielinski CC, Müller C. 1995. Failure to confirm presence of SV40 sequences in human tumors. Eur J Cancer 31A:1893.
37. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. 2005. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 353:375-381.
38. Lednicky JA, Arlington AS, Stewart AR, Dai XM, Wong C, Jafar S, Murphey-Corb M, Butel JS. 1998. Natural isolates of simian virus 40 from immunocompromised monkeys display extensive genetic heterogeneity: new implications for polyomavirus disease. J Virol 72:3980-3990.
39. Leithner A, Leithner A, Clar H, Weinhaeusel A, Radl R, Krippl P, Rehak P, Windhager R, Haas OA, Olschewski H. 2006. Mesothelioma mortality in Europe: impact of asbestos consumption and simian virus 40. Orphanet J Rare Dis 1:44.
40. Lerche NW. 2006. Personal communication.
41. Li YY, Perez HD, Zollner TM. 2006. Fatalities in natalizumab treatment - a 'no go' for leukocyte recirculation approaches? Expert Opin Ther Targets 10:489-499.
42. Lopez-Rios F, Illei PB, Rusch V, Ladanyi D. 2004. Evidence against a role for SV40 infection in human mesotheliomas and high risk of false-positive PCR results owing to presence of SV40 sequences in common laboratory plasmids. Lancet 364:1157-1166.
43. Major EO. 2001. Human polyomavirus. In: Knipe DM, Howley PM, editors. Fields virology. Philadelphia: Lippincott Williams and Wilkens. p 2175-2196.
44. Major EO, Neel JV. 1998. The JC and BK human polyoma viruses appear to be recent introductions to some South American Indian tribes: there is no serologic evidence of cross-reaction with the simian polyomavirus SV40. Proc Natl Acad Sci USA 95:15525-15530.
45. Manfredi JJ, Dong J, Liu W, Resnick-Silverman L, Qiao R, Chahinian P, Saric M, Gibbs AR, Phillips JI, Murray J, Axten CW, Nolan RP, Aaronson SA. 2005. Evidence against a role for SV40 in human mesothelioma. Cancer Res 65:2602-2609.
46. Mansfield KA. 2006. Personal communication.
47. Martini F, Corallini A, Balatti V, Sabbioni S, Pancaldi C, Tognon M. 2007. Simian virus 40 in humans. Infect Agent Cancer 2:13.
48. Melnick JL, Stinebaugh S. 1962. Excretion of vacuolating SV40 virus (papovavirus group) after ingestion as a contaminant of oral poliovaccine. Proc Soc Exp Biol Med 109:965-968.
49. Minor P, Pipkin PA, Cutler K, Dunn G. 2003. Natural infection and transmission of SV40. Virology 314:403-409.
50. Monaco MC, Atwood W, Gravell M, Tornatore C, Major E. 1996. JC virus infection of hematopoietic progenitor cells, primary B lymphocytes, and tonsillar stromal cells: implications for viral latency. J Virol 70:7004-7012.
51. Morris JA, Johnson KM, Aulisio CG, Chanock RM, Knight V. 1961. Clinical and serologic responses in volunteers given vacuolating virus (SV40) by respiratory route. Proc Soc Exp Biol Med 108:56-59.
52. Newman JS, Baskin GB, Frisque RJ. 1998. Identification of SV40 in brain, kidney, and urine of healthy and SIV-infected rhesus monkeys. J Neurovirol 4:394-406.
53. Norja P, Ubillos I, Templeton K, Simmonds P. 2007. No evidence for an association between infections with WU and KI polyomaviruses and respiratory disease. J Clin Virol 40:307-311.
54. Padgett BL, Zurheim GM, Walker DL, Eckroade RJ, Dessel BH. 1971. Cultivation of papova-like virus from human brain with progressive multifocal leukoencephalopathy. Lancet 1:1257-1260.
55. Pawlita M, Clad A, zur Hausen H. 1985. Complete DNA sequence of lymphotropic papovavirus: prototype of a new species of the polyomavirus genus. Virology 143:196-211.
56. Payton ME, d'Offay JM, Prado ME, Black DH, Damania B, White GL, Eberle R. 2004. Comparative transmission of multiple herpesviruses and simian virus 40 in a baboon breeding colony. Comp Med 54:695-704.
57. Perez-Losada M, Christensen RG, McClellan DA, Adams BJ, Viscidi RP, Demma JC, Crandall KA. 2006. Comparing phylogenetic codivergence between polyomaviruses and their hosts. J Virol 80:5663-5669.
58. Pipas JM. 1992. Common and unique features of T antigens encoded by the polyomavirus group. J Virol 66:3979-3985.
59. Schmidbauer M, Budka H, Shah KV. 1990. Progressive multifocal leukoencephalopathy (PML) in AIDS and in the pre-AIDS era: a neuropathological comparison using immunocytochemistry and in situ DNA hybridization for virus detection. Acta Neuropathol 80:375-380.
60. Shah KV. 1996. Polyomaviruses. In: Fields BN, Knipe DM, Howley PM, editors. Fields virology. Philadelphia: Lippincott-Raven Publishers. p 2027-2043.
61. Shein HM, Enders JF. 1962. Multiplication and cytopathogenicity of simian vacuolating virus 40 in cultures of human tissues. Proc Soc Exp Biol Med 109:495-500.
62. Simon MA, Ilyinskii PO, Baskin GB, Knight HY, Pauley DR, Lackner AA. 1999. Association of simian virus 40 with a central nervous system lesion distinct from progressive multifocal leukoencephalopathy in macaques with simian AIDS. Am J Pathol 154:437-446.
63. Stratton K, Almario DA, McCormick MC, editors. 2002. Immunization safety review: SV40 contamination of polio vaccine and cancer. Washington (DC): National Academies Press.
64. Strickler HD, Goedert JJ, Devesa SS, Lahey J, Fraumeni JF Jr, Rosenberg PS. 2003. Trends in US pleural mesothelioma incidence rates following simian virus 40 contamination of early poliovirus vaccines. J Natl Cancer Inst 95:38-45.
65. Strickler HD, Goedert JJ, Fleming M, Travis WD, Williams AE, Rabkin CS, Daniel RW, Shah KV. 1996. Simian virus 40 and pleural mesothelioma in humans. Cancer Epidemiol Biomarkers Prev 5:473-475.
66. Strickler HD, International SV40 Working Group. 2001. A multicenter evaluation of assays for detection of SV40 DNA and results in masked mesothelioma specimens. Cancer Epidemiol Biomarkers Prev 10:523-532.
67. Stuve O, Marra CM, Jerome KR, Cook L, Cravens PD, Cepok S, Frohman EM, Phillips JT, Arendt G, Hemmer B, Monson NL, Racke MK. 2006. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 59:743-747.
68. Sweet BH, Hillemann MR. 1960. The vacuolating virus, SV40. Proc Soc Exp Biol Med 105:420-427.
69. Testa JR, Carbone M, Hirvonen A, Khalili K, Krynska B, Linnainmaa K, Pooley FD, Rizzo P, Rusch V, Xiao GH. 1998. A multi-institutional study confirms the presence and expression of simian virus 40 in human malignant mesotheliomas. Cancer Res 58:4505-4509.
70. Trofe J, Gordon J, Roy-Chaudhury P, Koralnik I, Atwood W, Eash S, Alloway RR, Khalili K, Alexander JW, Woodle ES. 2004. Basic and clinical research in polyomavirus nephropathy. Exp Clin Transplant 2:162-173.
71. Valis JD, Newell N, Reissig M, Malherbe H, Kaschula VR, Shah KV. 1977. Characterization of SA12 as a simian virus 40-related papovavirus of chacma baboons. Infect Immun 18:247-252.
72. Vallbracht A, Löhler J, Gossmann J, Glück T, Petersen D, Gerth H, Gencic M, Dörries K. 1993. Disseminated BK type polyomavirus infection in an AIDS patient associated with central nervous system disease. Am J Pathol 143:29-39.
73. Van Assche G, Van Ranst M, Sciot R, Dubois B, Vermeire S, Noman M, Verbeeck J, Geboes K, Robberecht W, Rutgeerts P. 2005. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 353:362-368.
74. van Gorder MA, Della Pelle P, Henson JW, Sachs DH, Cosimi AB, Colvin RB. 1999. Cynomolgus polyoma virus infection: a new member of the polyoma virus family causes interstitial nephritis, ureteritis, and enteritis in immunosuppressed cynomolgus monkeys. Am J Pathol 154:1273-1284.
75. Viscidi RP, Rollinson DEM, Viscidi E, Clayman B, Rubalcaba E, Daniel R, Major EO, Shah KV. 2003. Serological cross-reactivities between antibodies to simian virus 40, BK virus, and JC virus assessed by virus-like-particle-based enzyme immunoassays. Clin Diagn Lab Immunol 10:278-285.
76. Völter C, zur Hausen H, Alber D, de Villiers EM. 1998. A broad spectrum PCR method for the detection of polyomaviruses and avoidance of contamination by cloning vectors. Dev Biol Stand 94:137-142.
77. Weber T, Trebst C, Frye S, Cinque P, Vago L, Sindic CJ, Schulz-Schaeffer WJ, Kretzschmar HA, Enzenberger W, Hunsmann G, Luke W. 1997. Analysis of the systemic and intrathecal humoral immune response in progressive multifocal leukoencephalopathy. J Infect Dis 176:250-254.
78. Yousry TA, Major EO, Ryschkewitsch C, Fahle G, Fischer S, Hou J, Curfman B, Miszkiel K, Mueller-Lenke N, Sanchez E, Barkhof F, Radue EW, Jager HR, Clifford DB. 2006. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354:924-933.
79. Zdziarski JM, Sarich NA, Witecki KE, Lednicky JA. 2004. Molecular analysis of SV40-CAL, a new slow-growing SV40 strain from the kidney of a caged New World monkey with fatal renal disease. Virus Genes 29:183-190.
80. zur Hausen H, Gissmann L. 1979. Lymphotropic papovaviruses isolated from African green monkey and human cells. Med Microbiol Immunol 167:137-153.